论文部分内容阅读
摘要目的检验地塞米松抑制效应是否会减少非小细胞肺癌病人肺及纵隔淋巴结转移的假阳性FDG摄取。方法本前瞻性研究已通过伦理委员会审查,并且所有受试者均已签订知情同意书。本次研究包括17例非小细胞肺癌病人,全部受试者行首次FDG PET/CT基线扫描,于服药(口服8 mg地塞米松)24 h后行第2次FDG PET/CT检查和手术。FDG的摄取使用五分法视觉评分(0-1分:阴性;2-4分:阳性)以及测量最大标准摄取值(SUVmax)来评估。数据分析使用Mann-Whitney U、Wilcoxon秩和检验或Spearman秩相关检
Abstract Objective To investigate whether the dexamethasone inhibitory effect can reduce false positive FDG uptake in lung and mediastinal lymph node metastasis in patients with non-small cell lung cancer. Methods This prospective study has been reviewed by ethics committees and all subjects have signed informed consent. The study included 17 patients with non-small cell lung cancer. All subjects underwent the first FDG PET / CT baseline scan and the second FDG PET / CT and surgery were performed 24 h after oral administration of 8 mg dexamethasone. FDG uptake was assessed using a five-point visual rating (0-1: negative; 2-4: positive) and measurement of the maximum standard uptake (SUVmax). Data analysis used Mann-Whitney U, Wilcoxon rank sum test or Spearman rank correlation test